| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.12 | 0.05 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.06 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.07 |